1. 25.8% of patients receiving chemotherapy for breast cancer experienced worsening frailty status. 2. Patients with both biomarkers (IL-6 and...

1. Objective response rate was 43.9%. Patients treated with selpercatinib also experienced improved overall response and time on treatment than...

1. Selpercatinib was found to have similar effective objective response rates compared to past studies in both treatment-naïve and chemotherapy...

1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a complete pathological response 2. Almost...

1. Pembrolizumab plus chemotherapy for triple-negative breast cancer significantly increased PFS and OS among patients whose tumours expressed PD-L1 with...

1. The rate of progression was 57% lower in the group receiving anal HSIL treatment as compared to the group...

1. Overall survival was significantly longer in patients taking darolutamide in tandem with androgen-deprivation therapy and docetaxel. 2. Frequency of...

1. Magnetic resonance imaging with targeted and standard biopsy was non-inferior for the detection of clinically significant cancers compared to...

1. Daratumumab therapy addition to bortezomib, cyclophosphamide, and dexamethasone showed improved cancer response in patients with systemic immunoglobulin light-chain amyloidosis....

1. Treatment with autologous CD34+ hematopoietic stem and progenitor cells transduced with human ADA via a lentiviral vector showed sustained...